Search This Blog

Monday, September 25, 2023

Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids

 Vapotherm Inc 

 announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention in children with acute severe asthma — a feasibility randomized controlled trial."

The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England.

Children who arrived at the hospital emergency department with acute, severe asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to HVNI or standard nasal oxygen therapy. 

While 86% (19/22) of children treated with standard oxygen required escalation of therapy, only 61% (17/28) of children treated with HVNI needed further escalation. 

In addition, children treated with HVNI met hospital discharge criteria in a median time of 29 hours, compared to 37 hours for those treated with standard oxygen.

According to the CDC and NHS, almost 5 million children in the U.S. and 1 million children in the U.K. have asthma. 

https://www.benzinga.com/general/biotech/23/09/34870546/vapotherms-asthma-therapy-more-effective-than-standard-oxygen-therapy-in-kids

Alvotech OKd in Japan on AVT04 (ustekinumab), a Biosimilar to Stelara®

 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that its commercialization partner in Japan, Fuji Pharma Co., Ltd. (“Fuji”), has received marketing approval for AVT04 (ustekinumab), a biosimilar to Stelara®, from the Japanese Ministry of Health, Labor and Welfare. Based on publicly available information, AVT04 is the first biosimilar to Stelara to be approved for sale in global markets. Global sales of Stelara reached over $10 billion for the twelve months preceding June 30, 2023, according to the manufacturer’s public filings, making it one of the world’s highest grossing biologics.

https://finance.yahoo.com/news/alvotech-announces-approval-japan-avt04-080000482.html

Alliance Global Partners Initiates Coverage on Vaccitech with Buy

 On September 25, 2023, Alliance Global Partners took the initiative to cover Vaccitech (NASDAQ:VACC) and bestowed it with a Buy rating, along with an announced price target of $12. Vaccitech, a prominent clinical-stage biopharmaceutical company, is dedicated to the development of immunotherapies and vaccines for both infectious diseases and cancer. Notably, the company has made remarkable strides in the field by collaborating with the prestigious University of Oxford and AstraZeneca to create a COVID-19 vaccine candidate. This candidate has exhibited promising results in clinical trials and has consequently received emergency use authorization in multiple countries

https://beststocks.com/alliance-global-partners-initiates-coverage-o/

Biden admin not protecting US from a 'known danger' at the border, China

 With the number of migrant encounters surging along the southern border, one policy expert warned we may soon face a war with China on U.S. soil.

"We have no idea of the number of Chinese males who come across and are not apprehended. So clearly we have a sabotage problem," Gatestone Institute senior fellow Gordon Chang said on "Mornings with Maria" Monday.

"We are going to have to worry about attacks on our military bases, on our shopping centers, on our reservoirs," he continued. "Just across the board, we are going to be fighting a war in Asia, on American soil. And that'll be the first time since 1812 that we will have to do so."

Customs and Border Protection (CBP) announced Friday that migrant encounters soared past 200,000 in August, hitting a new high for the calendar year and marking the highest August on record.

Last Wednesday, House Committee on Homeland Security Chairman Rep. Mark Green, R-Tenn., told host Maria Bartiromo that CBP has apprehended 18,000 Chinese nationals along the southern border.

The mostly military-age men from China are likely escaping due to "failure" with President Xi Jinping’s rule and declining economy, Chang claimed, while warning some in that group are "saboteurs."

"There are packs of Chinese males of 5 to 15, of military age, traveling without family members and pretending not to speak English," Chang described. "And as the chairman said, Border Patrol knows that some of these Chinese males have links to the military."

He also raised concerns about the underground biolab discovered by local officials in Reedley, California, who said they were unaware of what was taking place inside the previously vacant warehouse.

There, they had at least 20 pathogens. That's the official count. But there were almost a thousand mice that had been genetically engineered to transmit disease. So China is planning to kill Americans before the first shot is fired in Taiwan, Japan, the Philippines or wherever," Chang said.

President Xi is practicing a "rehearsal" of war with the U.S., Chang argued, while President Joe Biden "is subordinate to China."

https://www.foxbusiness.com/politics/biden-admin-protecting-us-known-danger-border-china-expert-warns

Trump pledges to investigate MSNBC parent company for ‘threatening treason’

 Former President Trump pledged to investigate Comcast, the parent company for NBC and MSNBC, if he is elected in 2024, saying it “will be thoroughly scrutinized for their knowingly dishonest and corrupt coverage of people, things, and events.”

“They are almost all dishonest and corrupt, but Comcast, with its one-side and vicious coverage by NBC NEWS, and in particular MSNBC, often and correctly referred to as MSDNC (Democrat National Committee!), should be investigated for its ‘Country Threatening Treason,” Trump wrote in a Truth Social post Sunday.

“I say up front, openly, and proudly, that when I WIN the Presidency of the United States, they and others of the LameStream Media will be thoroughly scrutinized for their knowingly dishonest and corrupt coverage of people, things, and events,” the former President wrote.

Trump also rehashed a phrase he has often used for news media in the past, calling it the “enemy of the people.”

“The Fake News Media should pay a big price for what they have done to our once great Country!” Trump added.

It’s unclear whether a particular story or report drew Trump’s ire. He sat down with new “Meet The Press” host Kristen Welker on NBC earlier this month.

During the interview, Trump repeated false claims that the 2020 election was stolen and rigged. His subsequent efforts to overturn the results and remain in power are at the center of federal charges against him in Washington, D.C., and state charges in Georgia.

MSNBC hosted a panel discussion Thursday on federal prosecutor Nora Dannehy saying she left the Durham investigation into Trump-Russia ties because of political meddling in the probe.

AbbVie EC ok in Large B-cell Lymphoma

 TEPKINLY® (epcoritamab) is the first and only subcutaneous bispecific antibody approved as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

  • Conditional marketing authorization approval from the European Commission is supported by data from the pivotal Phase 1/2 EPCORE™ NHL-1 clinical trial

  • TEPKINLY represents AbbVie's second approved hematological cancer treatment in the European Union

Biora IND Application to the U.S. FDA for BT-600 Program

 BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis

IND application is supported by robust clinical device function data

https://www.biospace.com/article/releases/biora-therapeutics-announces-submission-of-ind-application-to-the-u-s-fda-for-bt-600-program/